Mazdutide (10mg)
Mazdutide is a dual GLP-1/glucagon agonist. The 10 mg vial is more efficient for maintenance doses of 6–9 mg/wk. Weekly subcutaneous administration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full Mazdutide encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
A dual GLP-1/glucagon agonist. GLP-1 reduces appetite and enhances insulin secretion, while glucagon increases energy expenditure through thermogenesis and hepatic lipolysis.
Quick Start
- Reconstitution: Add 2.0 mL bacteriostatic water → 5.0 mg/mL.
- Weekly Range: 3–9 mg once weekly.
- Easy Dosing: At 5.0 mg/mL, 1 unit = 50 mcg.
- Storage: −20 °C / 2–8 °C after reconstitution.
Gradual Titration (2 mL = 5.0 mg/mL)
Route: Subcutaneous | Frequency: Once weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 3 mg | 60 Units (0.60 mL) |
| Weeks 5–8 | 4.5 mg | 90 Units (0.90 mL) |
| Weeks 9–12 | 6 mg | 2 × 60 Units (0.60 mL) |
| Weeks 13+ | 9 mg | 2 × 90 Units (0.90 mL) |
Studies report administration once weekly. One 10 mg vial is sufficient for ~1 week at 9 mg/wk.
Related compounds
Reconstitution Steps
- Withdraw 2.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial.
- Swirl gently until dissolved.
- Refrigerate at 2–8 °C.
Protocol Overview
- Goal: Weight management and glycemic control via GLP-1/glucagon agonism.
- Advantage: Fewer vials at maintenance doses.
Dosing Protocol
- Initiation: 3 mg/wk × 4 weeks.
- Titration: 4.5→6→9 mg every 4 weeks.
- Maintenance: 6–9 mg/wk.
- Break between cycles: After a cycle, a washout period of 4–8 weeks is recommended. Mazdutide has a long half-life—this pause allows for metabolic recovery.
Washout & Cycle Restart
When can I restart?
After a cycle, a washout period of 4–8 weeks is recommended. Mazdutide has a long half-life—this pause allows for metabolic recovery.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C.
- Reconstituted: 2–8 °C; use within 28 days.
Important Notes
- Start with a gradual titration from 3 mg.
- Monitor for GI side effects.
Regulatory Status
Mazdutide became the **first approved dual GLP-1/glucagon agonist worldwide** following approval by China's NMPA in July 2024 (as Xinermei®/Maiyoute). The FDA estimated approval timeline is 2028–2029. In the GLORY-1 trials it reported a ~15.1% change in body weight. It is not approved in the EU or the US.
Drugs (Springer): Mazdutide First Approval (2025)Regulatory history
(3)Approval by China's NMPA for obesity management (brand: Xinermei® / Maiyoute) — the first dual GLP-1/Glucagon agonist approved worldwide.
Drugs Springer 2025Phase 3 GLORY-1 results — mean weight reduction of ~15.1% over 48 weeks.
Lancet Diabetes 2024FDA Phase 2 ongoing; estimated US approval window 2028–2029 (Eli Lilly/Innovent pipeline).
FDA Approval Timeline (2026 update)
Potential Benefits & Side Effects
Potential Benefits:
- Weight change of ~14% over 24 weeks.
- Glycemic control.
- Reduction in hepatic steatosis.
- Fewer vials needed.
Potential Side Effects:
- GI: Nausea, diarrhea — generally mild.
- Mild increase in heart rate.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Potential thyroid C-cell risk
GLP-1/Glucagon dual agonist — same class-effect as other GLP-1 RAs.
📄 NMPA Approval Data — 2025References
- The Lancet Diabetes (2024) — Mazdutide Phase 3
View Source - Diabetes Care (2023) — Mazdutide Phase 2
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Mazdutide · Obesity / Type 2 diabetes (2025)
Obesity / Type 2 diabetes
NMPA China approved (2025)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →